Sector News

Medtronic wins conditional EU approval for $43 bln Covidien buy

November 28, 2014
Life sciences
(Reuters) – U.S. medical device maker Medtronic gained European Union regulatory approval on Friday for its $43 billion takeover of Covidien Plc after agreeing to sell its Irish rival’s drug-coated balloon catheter business.
 
The deal will put Medtronic on about the same footing as global leader Johnson & Johnson and take it a step closer to moving to Ireland where it could have access to revenues earned outside the United States without paying taxes on them.
 
The European Commission said the sale of Covidien’s Stellarex business would sooth concerns that the deal would reduce innovation in this area. Covidien clinched a deal to sell Stellarex to Spectranetics on Nov. 3.
 
U.S. authorities cleared the takeover earlier this week with the same condition. (Reporting by Foo Yun Chee; editing by Philip Blenkinsop)

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach